Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

Trial Profile

Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2015

At a glance

  • Drugs DNX 2401 (Primary)
  • Indications Anaplastic astrocytoma; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions
  • Sponsors DNAtrix
  • Most Recent Events

    • 20 Feb 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov
    • 17 Jun 2013 Data will be presented at the Replicating Oncolytic Virus Therapeutic meeting, according to a DNAtrix media release.
    • 10 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top